182 related articles for article (PubMed ID: 22005473)
21. Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP).
Parra HS; Tixi L; Latteri F; Bretti S; Alloisio M; Gravina A; Lionetto R; Bruzzi P; Dani C; Rosso R; Cosso M; Balzarini L; Santoro A; Ardizzoni A
Cancer; 2001 Aug; 92(3):650-6. PubMed ID: 11505411
[TBL] [Abstract][Full Text] [Related]
22. A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results.
Pass HI; Brewer GJ; Dick R; Carbone M; Merajver S
Ann Thorac Surg; 2008 Aug; 86(2):383-9; discussion 390. PubMed ID: 18640301
[TBL] [Abstract][Full Text] [Related]
23. Systemic drug therapy of malignant pleural mesothelioma.
Ardizzoni A; Grossi F; Pennucci MC
Monaldi Arch Chest Dis; 1998 Apr; 53(2):236-40. PubMed ID: 9689814
[TBL] [Abstract][Full Text] [Related]
24. Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy.
Papa S; Popat S; Shah R; Prevost AT; Lal R; McLennan B; Cane P; Lang-Lazdunski L; Viney Z; Dunn JT; Barrington S; Landau D; Spicer J
J Thorac Oncol; 2013 Jun; 8(6):783-7. PubMed ID: 23571475
[TBL] [Abstract][Full Text] [Related]
25. Targeted therapies in malignant pleural mesothelioma: a review of clinical studies.
Greillier L; Marco S; Barlesi F
Anticancer Drugs; 2011 Mar; 22(3):199-205. PubMed ID: 21263312
[TBL] [Abstract][Full Text] [Related]
26. [Systemic Treatment of Malignant Pleural Mesothelioma].
Nakano T
Gan To Kagaku Ryoho; 2017 Dec; 44(13):2041-2047. PubMed ID: 29361614
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of phase 1 trials in malignant pleural mesothelioma: description of a series of patients at a single institution.
Raphael J; Le Teuff G; Hollebecque A; Massard C; Bahleda R; Margery J; Besse B; Soria JC; Planchard D
Lung Cancer; 2014 Aug; 85(2):251-7. PubMed ID: 24882384
[TBL] [Abstract][Full Text] [Related]
28. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
29. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
Santoro A; O'Brien ME; Stahel RA; Nackaerts K; Baas P; Karthaus M; Eberhardt W; Paz-Ares L; Sundstrom S; Liu Y; Ripoche V; Blatter J; Visseren-Grul CM; Manegold C
J Thorac Oncol; 2008 Jul; 3(7):756-63. PubMed ID: 18594322
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy for malignant pleural mesothelioma.
Janne PA
Clin Lung Cancer; 2003 Sep; 5(2):98-106. PubMed ID: 14596692
[TBL] [Abstract][Full Text] [Related]
31. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
Fennell DA; Parmar A; Shamash J; Evans MT; Sheaff MT; Sylvester R; Dhaliwal K; Gower N; Steele J; Rudd R
J Clin Oncol; 2005 Jan; 23(1):184-9. PubMed ID: 15625372
[TBL] [Abstract][Full Text] [Related]
32. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study.
Astoul P; Picat-Joossen D; Viallat JR; Boutin C
Cancer; 1998 Nov; 83(10):2099-104. PubMed ID: 9827714
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma.
Fennell DA; C Steele JP; Shamash J; Sheaff MT; Evans MT; Goonewardene TI; Nystrom ML; Gower NH; Rudd RM
Lung Cancer; 2005 Feb; 47(2):277-81. PubMed ID: 15639727
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
Stebbing J; Powles T; McPherson K; Shamash J; Wells P; Sheaff MT; Slater S; Rudd RM; Fennell D; Steele JP
Lung Cancer; 2009 Jan; 63(1):94-7. PubMed ID: 18486273
[TBL] [Abstract][Full Text] [Related]
35. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
Ceresoli GL; Zucali PA; De Vincenzo F; Gianoncelli L; Simonelli M; Lorenzi E; Ripa C; Giordano L; Santoro A
Lung Cancer; 2011 Apr; 72(1):73-7. PubMed ID: 21216487
[TBL] [Abstract][Full Text] [Related]
36. Pemetrexed in malignant pleural mesothelioma and the clinical outcome.
Knuuttila A; Salomaa ER; Saikkonen S; Hurme S; Salo J
Clin Respir J; 2012 Apr; 6(2):96-103. PubMed ID: 21651743
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Spigel DR; Greco FA; Rubin MS; Shipley D; Thompson DS; Lubiner ET; Eakle JF; Quinn R; Burris HA; Hainsworth JD
Lung Cancer; 2012 Aug; 77(2):359-64. PubMed ID: 22560921
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.
Lu C; Perez-Soler R; Piperdi B; Walsh GL; Swisher SG; Smythe WR; Shin HJ; Ro JY; Feng L; Truong M; Yalamanchili A; Lopez-Berestein G; Hong WK; Khokhar AR; Shin DM
J Clin Oncol; 2005 May; 23(15):3495-501. PubMed ID: 15908659
[TBL] [Abstract][Full Text] [Related]
39. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
Zucali PA; Simonelli M; Michetti G; Tiseo M; Ceresoli GL; Collovà E; Follador A; Lo Dico M; Moretti A; De Vincenzo F; Lorenzi E; Perrino M; Giordano L; Farina G; Santoro A; Garassino M
Lung Cancer; 2012 Mar; 75(3):360-7. PubMed ID: 21937142
[TBL] [Abstract][Full Text] [Related]
40. Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma.
Ak G; Metintas M; Metintas S; Yildirim H; Ozkan R; Ozden H
Eur J Radiol; 2010 Apr; 74(1):130-5. PubMed ID: 19268516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]